Ultraviolet Light (UV) Therapy for Atopic Dermatitis: Double blind, randomised trial of narrow band (TLO1) versus UVA versus placebo.

INTERVENTION: 1. TLO1‐UVB 2. UVA 3. Placebo phototherapy Initial dose of UVA will be 5 J/sq cm, increased to 10 then 15 J/sq cm as tolerated. Initial dose of TLO1 will be increased from 0.4, to 0.6, to 0.9, to 1.2 J/sq cm until mild erythema develops and then according to a defined protocol. Visible fluorescent lamps will be employed for placebo treatments. Treatments will be twice weekly for a maximum of 24 exposures. CONDITION: Skin and connective tissue diseases: ; Skin and Connective Tissue Diseases ; Atopic Dermatitis PRIMARY OUTCOME: Preliminary work suggests a response should be detectable after 12 treatments. Physical signs of disease activity, overall extent of disease, patient symptoms and quantities of topical steroids used will be assessed, by an observer who is unaware of treatment received, at baseline, after 6, 12, 18 and 24 treatments and 3 months after stopping phototherapy. SECONDARY OUTCOME: Not provided at time of registration INCLUSION CRITERIA: Patients, aged 16‐65 years with moderate severe atopic dermatitis.